Product image of Nuvaxovid Jn.1 (Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv) supplied by GNH India

Nuvaxovid Jn.1

Active Ingredient:
Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv
Origin:
EU

Nuvaxovid Jn.1 (Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv)

Matrix M, the active ingredient in Nuvaxovid Jn.1, is a recombinant protein subunit vaccine presented as a 0.5 mL dose for intramuscular use. It targets the SARS‑CoV‑2 Omicron JN.1 variant spike protein to stimulate protective immunity in adults.

GNH India supplies Nuvaxovid Jn.1 as a licensed, GDP‑compliant international pharmaceutical supplier serving hospitals and pharmacies worldwide.

Manufacturer / TM Owner

Novavax Cz A.S.

1
Pack/s
This product is added to your enquiry list

Request a Quote

Please fill out the form below and our team will get back to you shortly with pricing and further information.

A minimum order value applies. Our team will confirm the exact amount or quantity after reviewing your requirements.

Indications & Clinical Uses

Nuvaxovid Jn.1 is designed to induce immunity against the SARS‑CoV‑2 Omicron JN.1 variant and is indicated for:

  • Primary vaccination: Provides protective immunity in individuals not previously vaccinated against COVID‑19.
  • Booster vaccination: Enhances immune response in persons who have completed a primary COVID‑19 vaccine series.
  • Heterologous boosting: Can be used to boost immunity after a primary series with a different COVID‑19 vaccine platform.

How It Works

  • Nuvaxovid Jn.1 contains a recombinant spike protein of the SARS‑CoV‑2 Omicron JN.1 variant expressed in Sf9 insect cells. The protein is formulated with an adjuvant that promotes antigen uptake and presentation, leading to activation of B‑cells and T‑cell responses that generate neutralising antibodies against the targeted variant.

Side Effects

Adverse reactions reported with Nuvaxovid Jn.1 are generally mild to moderate and resolve without medical intervention.

Common Side Effects

  • Injection site pain: mild discomfort at the injection site.
  • Fatigue: transient feeling of tiredness.
  • Headache: mild to moderate headache.
  • Myalgia: muscle aches.
  • Fever: low‑grade temperature elevation.
  • Nausea: occasional feeling of queasiness.

Serious or Rare Side Effects

  • Anaphylaxis: severe allergic reaction requiring immediate medical care.
  • Guillain‑Barré syndrome: rare neurological disorder.
  • Thrombosis with thrombocytopenia: uncommon clotting event.
  • Myocarditis/pericarditis: inflammation of heart muscle or surrounding tissue.
  • Severe allergic reactions: including angio‑edema.
  • Immune‑mediated disorders: such as vasculitis.

Precautions & Warnings

Before administering Nuvaxovid Jn.1, consider the following precautions:

  • Contraindication: If the re‑    ...

-  ...  .... ... ...  ...  ....  ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... ... … ... ... ... ... ... .... ... ... ... ... ... ... .... …  -  … … … ... ... ... ...

Avoid Interactions

  • ...

Published by

GNH India Pharmaceuticals Limited

Licensed pharmaceutical supplier

Last updated:

Disclaimer

At GNH India, we aim to provide information that is expert-reviewed, accurate, and reliable. However, all content on this platform is intended for general informational purposes only and does not constitute professional medical advice, diagnosis, or treatment. While efforts are made to maintain accuracy and currency, the information may contain errors, omissions, or may not reflect the latest developments. Always consult a qualified healthcare professional regarding any medical concerns.

All product names, brand names, trademarks and registered trademarks displayed on this website are the property of their respective owners. This website and its operator are not affiliated with, endorsed by, or authorized by any such trade mark owners unless expressly stated. Any reference to product names or trademarks is made solely for descriptive and informational purposes. No commercial relationship, sponsorship, approval, or association with any trademark owner should be inferred. Information provided herein does not constitute promotion, advertising, or an offer for sale of any medicinal product and is intended solely for general informational purposes.

All trademarks and brand names displayed on this website are used strictly in accordance with the provisions of the Trade Marks Act, 1999, specifically Sections 30 and 30(1) governing fair use. Trademark ownership has been accurately attributed under the "Manufacturer/ TM Owner" section in compliance with statutory requirements.

Related Products

Other formulations containing Matrix M, Sars-Cov-2, Variant Omicron Jn.1, Spike Protein, Recombinant, Expressed In Sf9 Cells Deriv

A

A
A

A
A

A
A

A

Browse all products →

Ordering Process

Simple, Secure, and Seamless

Learn how our streamlined ordering process guarantees fast, compliant, and reliable access to essential medicines worldwide.

Quote request form

01

Submit Quote Request Form

Tell us what medications you need by filling out our simple form and uploading a valid document.

Price estimate review

02

We Review & Send Estimate

Our licensed pharmacists will verify your details and provide you with a detailed cost estimate.

Secure payment

03

Confirm & Make Payment

Discuss any queries, approve the estimate, and complete your payment.

Worldwide delivery

04

Get Delivered

Your medicines, safely packed and delivered to your door or nearest airport — hassle-free.

Regulatory recognitions

Quality You Can Trust

Our internationally recognized certifications underscore our commitment to safety, quality, and excellence.

SGS GSDP Certification

GSDP Compliant from SGS

URS ISO 9001

URS ISO 9001 Certification

FDA Maharashtra

Licensed by FDA Maharashtra

IEC License DGFT

IEC License issued by DGFT